Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIVI-I: Microplasmin Dose-Escalation in VMT
NCT00123279Phase 2Completed
- Sponsor
- Oxurion
- Start
- Dec 2004
- Primary completion
- Feb 2007
- Modality
- Therapeutic Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label trial of ocriplasmin in vitreomacular traction (VMT) and macular hole (6 arms), sponsored by Oxurion. Primary endpoint: Grade of Posterior Vitreous Detachment at 180 days. Started Dec 2004; status: completed.
02
Drugs
ocriplasmin
03
Conditions
vitreomacular traction (VMT)macular hole
Beyond the preview
Go deeper on NCT00123279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00123279.